Immediate steps for primary care clinicians receiving a newborn’s positive screen result
Introduction
Multiple carboxylase deficiency (MCD) encompasses the more specific diagnoses of biotinidase deficiency and holocarboxylase synthetase deficiency. Holocarboxylase synthetase (HLCS) deficiency results in defective attachment of biotin to biotin-dependent carboxylases (propionyl CoA carboxylase, beta-methylcrotonyl CoA carboxylase, acetyl-CoA carboxylase, and pyruvate carboxylase) and typically presents neonatally.1 Alternatively, biotinidase deficiency results in impaired recycling of biotin and presents slightly later during infancy. Biotinidase deficiency can further be subclassified as profound or partial biotinidase deficiency, the latter of which rarely experience symptoms.2 Both types of MCD ultimately result in a secondary deficiency of biotin-dependent enzymes, causing impaired gluconeogenesis and the accumulation of multiple toxic organic acids involved in propionic acid and leucine metabolism. Clinically patients may present with an eczematous rash, alopecia, hypotonia, poor feeding, developmental delays, hearing loss, seizures, and coma, if untreated.3
Other names: Holocarboxylase synthetase (HCLS) deficiency, Biotinidase deficiency, Partial biotinidase deficiency, Profound biotinidase deficiency
Keywords: Acidosis, alopecia, amino acid metabolism, autosomal recessive, biotin, biotinidase, carboxylases, hyperammonemia, hypoglycemia, hypotonia, infant, leucine, metabolic acidosis, newborn screening, organic acidemia, organic acids, tandem mass spectrometry
Disorder Category
Organic acidemia
Abnormal Finding
Elevated C5:1 (methylcrotonyl or tiglyl carnitine), C5-OH (3-hydoxyisovaleryl carnitine), or C3 (propionyl carnitine)
Tested By
Tandem mass spectrometry (MS/MS); sensitivity: NA; specificity: NA
Clinical Characteristics
With treatment, most children will have normal growth and development, though some with holocarboxylase synthetase deficiency specifically may only partially respond to therapy or not at all.
Without treatment, repeated episodes of metabolic acidosis lead to severe impairment or death. Infants may show symptoms within a few hours or days of life, while other infants may not have symptoms until 2 years of age. Children may be healthy between metabolic crisis episodes. The majority with partial biotinidase deficiency will not experience symptoms, even without treatment.
Initial Presentation
Initial signs/symptoms may include:
- Poor feeding
- Vomiting
- Skin rashes
- Hearing loss
- Lethargy
- Hypotonia
- Irritability
- Lab findings:
- Metabolic acidosis
- Hyperammonemia
- Ketonuria
- Thrombocytopenia
- Hypoglycemia
If not treated promptly, patients may experience:
- Global developmental delay
- Alopecia
- Eczematous skin rash
- Hearing loss
- Hyperventilation/apnea
- Spasticity
- Seizures
- Brain damage
- Death
Treatment consists of biotin supplementation at high doses, avoidance of fasting, and prompt treatment of infections, fever, and gastroenteritis with fluids containing glucose.4
Incidence
Approximately 1:87,000 live births5
Inheritance
Autosomal recessive
Next Steps After a Positive Screen
- Contact the family and evaluate the infant for poor feeding, vomiting, or lethargy.
- Provide emergency treatment, referral for signs/symptoms of hypoglycemia, metabolic acidosis, ketonuria, or seizures.
Confirming the Diagnosis
- To confirm the diagnosis, work with newborn screening services.
- Additional testing may include a quantitative plasma acylcarnitine profile, a serum biotinidase assay, and a urine organic acids assay. Definitive confirmation requires an enzyme assay in white blood cells, fibroblasts, or DNA testing. An enzyme assay may miss mild forms due to the presence of biotin in culture media.
If the Diagnosis is Confirmed
- For evaluation and ongoing collaborative management, consult Medical Genetics.
- Educate the family about signs, symptoms, and the need for urgent care when the infant becomes ill.
- Biotin supplements are indicated.
- For those identified after irreversible consequences, assist in management.
References
1. Wang X, Li Y, Zhang J, et al. Holocarboxylase synthetase deficiency: pathogenesis, clinical spectrum, diagnostic approaches, and therapeutic strategies. Front Cell Dev Biol. 2024;12:42324336. doi:10.3389/fcell.2024.1234567
2. Wolf B. Biotinidase deficiency. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. GeneReviews®. University of Washington, Seattle; March 24, 2000. Updated June 9, 2022
3. Wolf B. Biotinidase deficiency: What have we learned in forty years? Mol Genet Metab. 2023;139(2):37027963. doi:10.1016/j.ymgme.2023.107584
4. Van Hove JLK, Josefsberg S, Freehauf C, et al. Management of a patient with holocarboxylase synthetase deficiency. Mol Genet Metab. 2008;95(4):201-205. doi:10.1016/j.ymgme.2008.09.006
5. 5. Holocarboxylase synthetase deficiency. MedlinePlus. May 1, 2020. Accessed June 26, 2026. https://medlineplus.gov/genetics/condition/holocarboxylase-synthetase-deficiency/#references
Article History
This article was originally published on the Medical Home Portal and updated before publication on TRiP. The Medical Home Portal, retired in July 2024, provided diagnosis and management information for pediatric conditions, guidance for immediate steps after a positive newborn screen result, and in-depth family education to improve outcomes for children with complex medical care needs. The full archive can be found at the Medical Home Portal Archive.
Topical Reviews in Pediatrics (TRIP) includes archival and updated content from the Medical Home Portal and features new, contemporary topics in pediatrics.
- 2022 revision: Hannah Holik, MD A; Kimberly Stowers, MDA; Brian Shayota, MDA; Nancy C. RoseR
- 2012 revision: Kimberly Hart, MS, LCGCA
- 2011 first publication: Nicola Longo, MD, PhDA
AAuthor; CAContributing Author; SASenior Author; RReviewer
